Irritable Bowel Syndrome
Public-private partnership initiative develops core diagnostic criteria for abdominal, pelvic, and urogenital pain associated with irritable bowel syndrome.
The FDA has accepted the supplemental New Drug Application for Trulance for the treatment of irritable bowel syndrome with constipation.
The efficiency of self-administered hypnotherapy is equivalent to that of in-office hypnotherapy in relieving pediatric irritable bowel syndrome or functional abdominal pain.
Probiotics may alleviate pain in the short-term in children with recurrent abdominal pain.
The FDA is warning patients and healthcare professionals that Viberzi tablets should not be used in patients without a gallbladder due to an increased risk of developing serious pancreatitis
Most frequent upper functional GI disorders in IBS were functional dyspepsia, belching disorders
Tarantula toxin specifically mediates mechanonociception
Clinical Pain Advisor Articles
- Supervised Injection Sites: Facts, Information, Pros, and Cons
- Chronic Pain May Be a Contributing Factor to Suicide
- Striking a Balance Between Opioid Surveillance and Patient Privacy
- Demographic Characteristics of Pregnant Women With Opioid Use Disorder
- Effects of Mindfulness Therapy, Pharmacologic Prophylaxis on Catecholamine Levels in Migraine
- Perioperative Pain Management in Patients With Opioid Use Disorder
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Reviewing the Efficacy of Invasive Procedures for Chronic Back, Knee Pain
- Antidepressant Effects of Ketamine Appear to Require Opioid System Activation
- Lower Weighting of Hand Cortical Representations in CRPS
- Predicting Success of Focal Nerve Surgery Based on Diagnostic Block Response
- Aetna-CVS Merger Approved
- FDA Announces Draft Guidance for Consumer OTC Access to Previously Prescription Drugs
- Maryland Legislature: Will Federal Courts Permit State Regulation of Drug Prices?